Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 29 April 2022
Bagsværd, Denmark, 29 April 2022 – In accordance with Section 32 of the Danish Capital Markets Act, Novo Nordisk A/S is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred.
Referring to Company Announcement no 31/2022 dated 27 April 2022, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk A/S as per 29 April 2022.
|Number of shares |
(of DKK 0.20 each)
|Share capital (nominal value, DKK)||Number of votes1|
1 Each A share of DKK 0.01 carries 10 votes, whereas each B share of DKK 0.01 carries one vote. Thus, each A share of DKK 0.20 carries 200 votes and each B share of DKK 0.20 (the present denomination of the company's shares) carries 20 votes. Treasury shares are included in the table above but voting rights of treasury shares are suspended at the general meetings of Novo Nordisk A/S.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, and YouTube.
|Ambre Brown Morley||+45 3079 email@example.com|
|Natalia Salomao Abrahao (US)||+1 848 304 firstname.lastname@example.org|
|Daniel Muusmann Bohsen||+45 3075 email@example.com|
|Ann Søndermølle Rendbæk||+45 3075 firstname.lastname@example.org|
|David Heiberg Landsted||+45 3077 email@example.com|
|Jacob Martin Wiborg Rode||+45 3075 firstname.lastname@example.org|
|Mark Joseph Root (US)||+1 848 213 email@example.com|
Company announcement No 35 / 2022
Upcoming Life Sciences Events
- June 2022
- Digital RESI
- Product & Company Valuation Course
- BIO International Convention 2022